期刊文献+

2-氨基-5-甲氧基-4-[3-(吡咯烷-1-基)丙氧基]苯胺合成

Synthesis of 2-amino-5-methoxy-4-[3-(pyrrolidin-1-yl)propoxy]aniline
原文传递
导出
摘要 以2-氨基-4-羟基-5-甲氧基苯甲酸甲酯(化合物2)和1-(3-羟丙基)四氢吡咯(化合物3)为原料,通过光延反应得到2-氨基-5-甲氧基-4-[3-(吡咯烷-1-基)丙氧基]苯胺(化合物1)。通过1H-NMR和ESI-MS对化合物1的结构进行了表征,并对反应条件进行了优化。确定的最佳的反应条件为:反应溶剂为四氢呋喃,n(化合物2)∶n(偶氮二甲酸二叔丁酯)∶n(化合物3)=1∶1.2∶2.0,n(三苯基膦)∶n(化合物2)=1∶1,反应时间为3h。在此反应条件下,化合物1的收率可达到65.4%。 The target compound 2-amino-5-methoxy-4-[3-(pyrrolidin-1-yl)propoxy] aniline(1) was synthesized from 2-amino-4-hydroxy-5-methoxybenzoate(2) and 1-(3-hydroxypropyl)-pyrolidine(3),The structures of the target compound 1 were characterized by 1H-NMR and ESI-MS and the reaction conditions were optimized.The research showed that the optimization conditions were terthydrofuran as sollvent, n(2) ∶n(Di-tert-butyl azodicarboxylate) ∶n(3)=1∶1.2∶2.0,n(triphenylphosphine)/n(2)=1∶1,reaction time was 3 h.The yield of the target compound 1 was 65.4% when the reaction was conducted under the optimization conditions.
作者 刘懿 吕莹莹 李改园 程越 蒋伟 高艳蓉 唐文强 LIU Yi;LYU Ying-ying;LI Gai-yuan;CHENG Yue;JIANG Wei;GAO Yan-rong;TANG Wen-qiang(School of Pharmacy,Shaanxi Institute of International Trade Commerce,Xi’an 712046,China;Co-Innovation Center of Shaanxi Green Manufacturing Technology of Traditional Chianese Medicine,Xi’an 712046,China)
出处 《精细与专用化学品》 CAS 2021年第6期44-47,共4页 Fine and Specialty Chemicals
基金 2020年国家级大学生创新创业训练计划项目(S202013123001) 2020年陕西国际商贸学院校级课题(SMXY202021)。
关键词 苯胺衍生物 吡咯烷侧链 合成 aniline derivative pyrrolidine side chain synthesis
  • 相关文献

参考文献1

二级参考文献13

  • 1Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies [J]. Leukemia, 2011, 25 (11) : 1751-1759. 被引量:1
  • 2Hart S, Goh KC, Novotny-Diermayr V, et al. Pacritinib (SB 1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia [J]. Blood Cancer J, 2011, 1 (11) : e44. 被引量:1
  • 3Derenzini E, Younes A. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib [J]. Expert Opin lnv Drug, 2013, 22 (6) : 775-785. 被引量:1
  • 4William AD, Lee AC, Blanchard S, et al. Discovery of the macrocycle 11 - (2-pyrrolidin- I -yl-ethoxy) - 14,19-dioxa- 5,7,26-triazatetracyclo [ 19.3.1.12,6.18,12] heptacosa- 1 25,226,3,5, 8,10,1227,16,21,23-decaene(SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma [J]. J Med Chem, 2011, 54(13) : 4638-4658. 被引量:1
  • 5William AD, Lee AC, Goh KC, et al. Discovery of kinase spectrum selective macrocycle (16E) -14-methyl-20-oxa- 5,7,14,26-traazatetracyclo [ 19.3.1.12,6.18.12] heptacosa- 125,226,3,5,827,9,11,16,21,23-decaene (SB 1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer [J]. J Med Chem, 2011, 55 (1): 169-196. 被引量:1
  • 6史蒂芬妮·班尼乔,哈瑞许·库玛·密索·那卡伽,迈克尔·安克森,等.氧连接的嘧啶衍生物:中国,101360751[P].2009-02-04. 被引量:1
  • 7Chen DZ. Indole sustituted pyrimidines and use thereof in the treatment of cancer: WO, 2008060248 [P]. 2008-05-22. 被引量:1
  • 8Penning TD, Chandrakumar NS, Chen BB, et al. Structure- activity relationship studies on 1-[2-(4-phenylphenoxy)- ethyl] pyrrolidine (SC-22716), a potent inhibitor of leukotriene A4 (LTA4) hydrolase [J]. J Med Chem, 2000, 43 (4) : 721-735. 被引量:1
  • 9Gandhi A, Dimartino J, Chopra R. Methods for the treatment of locally advanced breast cancer: WO, 2014039960 [P]. 2014-03-13. 被引量:1
  • 10迪莫克B,李静霞,威廉AD.11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.12,6,18,12]-二十七碳-125,226,3,5,8,10,1227,16,21,23-十烯柠檬酸盐:中国,102282148[P].2011-12-14. 被引量:1

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部